Conjugated anti-cMet antibody has been reported to be able to light up small tumours in vivo. If that result proves valid in clinical settings, then a wider implication arises: by conjugating therapeutic agents to the antibody, the technology might be used in diagnostic imaging and in therapies. The gene discussed is MET; the disease is neoplasm.